Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Archives of Internal Medicine

Volumn 168, Issue 2, 2008, Pages 207-217

  Wright Jr , Jackson T ^a   Harris Haywood, Sonja ^a   Pressel, Sara ^b   Barzilay, Joshua ^c   Baimbridge, Charles ^b   Bareis, Charles J ^d   Basile, Jan N ^e   Black, Henry R ^f   Dart, Richard ^g   Gupta, Alok K ^h   Hamilton, Bruce P ⁱ   Einhorn, Paula T ^j   Julian Haywood, L ^k   Jafri, Syed Z A ^l   Louis, Gail T ^m   Whelton, Paul K ⁿ   Scott, Cranford L ^o   Simmons, Debra L ^p   Stanford, Carol ^q   Davis, Barry R ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c KAISER PERMANENTE   (United States)

^d Department of Medicine   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MARSHFIELD CLINIC   (United States)

^h PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

ⁱ BALTIMORE VA MEDICAL CENTER   (United States)

^j NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^k LAC USC MEDICAL CENTER   (United States)

^l Fargo VA Medical Center   (United States)

^m TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

ⁿ LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^o Cranford L Scott MD Inc   (United States)

^p UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^q UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; ATENOLOL; CHLORTALIDONE; CLONIDINE; DOXAZOSIN MESYLATE; HYDRALAZINE; LISINOPRIL; RESERPINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; STROKE; TRIACYLGLYCEROL BLOOD LEVEL;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; CHLORTHALIDONE; DOUBLE-BLIND METHOD; DOXAZOSIN; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPERTENSION; LISINOPRIL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; TREATMENT OUTCOME;

EID: 38749150577     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2007.66     Document Type: Article

References (32)

1. Hall WD, Clark LT, Wenger NK, et al; African-American Lipid and Cardiovascular Council. The metabolic syndrome in African Americans: a review. Ethn Dis. 2003;13(4):414-428.
2. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433-438.
3. Eckel RH, Kahn R, Robertson RM, Rizza RA. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation. 2006;113(25):2943-2946.
4. Mykkänen L, Kuusisto J, Pyörälä K, Laakso M, Haffner SM. Increased risk of noninsulin-dependent diabetes mellitus in elderly hypertensive subjects. J Hypertens. 1994;12(12):1425-1432.
5. Giles TD, Sander GE. Pathophysiologic, diagnostic, and therapeutic aspects of the metabolic syndrome. J Clin Hypertens (Greenwich). 2005;7(11):669-678.
6. Mancia G. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetol. 2005;42(suppl 1):S17-S25.
7. Wagh A, Stone NJ. Treatment of metabolic syndrome. Expert Rev Cardiovasc Ther. 2004;2(2):213-228.
8. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [published corrections appear in JAMA. 2003;289(2):178 and JAMA. 2004;291(18):2196]. JAMA. 2002;288(23):2981-2997.
9. Wright JT Jr, Dunn JK, Cutler JA, et al; ALLHAT Collaborative Research Group. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005;293(13):1595-1608.
10. Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165(8):936-946.
11. Rahman M, Pressel S, Davis BR, et al; ALLHAT Collaborative Research Group. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med. 2006;144(3):172-180.
12. Davis BR, Cutler JA, Gordon DJ, et al; ALLHAT Research Group. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;9(4, pt 1):342-360.
13. Zhu S, Wang Z, Heshka S, Heo M, Faith MS, Heymsfield SB. Waist circumference and obesity-associated risk factors among whites in the Third National Health and Nutrition Examination Survey: clinical action thresholds. Am J Clin Nutr. 2002;76(4):743-749.
14. Pyörälä K, Ballantyne CM, Gumbiner B, et al; Scandinavian Simvastatin Survival Study (4S). Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 2004;27(7):1735-1740.
15. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new world-wide definition: a consensus statement from the International Diabetes Federation. Diabet Med. 2006;23(5):469-480.
16. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus α-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2003;42(3):239-246.
17. Whelton PK, Barzilay J, Cushman WC, et al; ALLHAT Collaborative Research Group. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165(12):1401-1409.
18. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265(24):3255-3264.
19. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR; SHEP Collaborative Research Group. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95(1):29-35.
20. Black HR, Elliott WJ, Grandits G, et al; CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289(16):2073-2082.
21. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity: the Swedish Trial in Old Patients With Hypertension-2 Study. Lancet. 1999;354(9192):1751-1756.
22. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) [published correction appears in Lancet. 2000;356(9228):514]. Lancet. 2000;356(9227):366-372.
23. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527-1535.
24. Turnbull F, Neal B, Algert C, et al; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165(12):1410-1419.
25. Black HR, Davis BR, Barzilay J, et al. Clinical outcomes in non-diabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial hypertension therapy: a report from the ALLHAT study. Diabetes Care. In press.
26. Weber MA. Hypertension, the metabolic syndrome, and the risk of developing diabetes: is it time to change the guidelines? J Clin Hypertens (Greenwich). 2004;6(8):425-427.
27. Messerli FH, Weber MA. Long-term cardiovascular consequences of diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors. JAMA. 2003;289(16):2067-2068.
28. Woerle HJ, Pimenta WP, Meyer C, et al. Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin A1c values. Arch Intern Med. 2004;164(15):1627- 1632.
29. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia. 2006;49(8):1761-1769.
30. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43(5):963-969.
31. Barzilay JI, Davis BR, Cutler JA, et al; ALLHAT Collaborative Research Group. Fasting glucose levels and incident diabetes mellitus in older non-diabetic adults randomized to three different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2006;166(20):2191-2201.
32. Bosch J, Yusuf S, Gerstein HC, et al; DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355(15):1551-1562.